Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Curt D Furberg

Showing results (71-80 of 169) with videos related to

Pageof 17
Sort By:
Progress in Cardiovascular Diseases|May 11, 2015
Is the Guideline Process Replicable and, if Not, What Does This Mean?Allan Sniderman, Curt D Furberg, Peter P Toth, et al.
Journal of Clinical Lipidology|December 3, 2010
Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?Allan Sniderman, Matt McQueen, John Contois, et al.
Journal of Clinical Lipidology|September 29, 2016
An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoBAllan D Sniderman, Peter P Toth, George Thanassoulis, et al.
Journal of Clinical Lipidology|December 3, 2010
When is equal not equal?Allan D Sniderman, Ken Williams, Matthew J McQueen, et al.
BMJ (Clinical Research Ed.)|June 16, 2011
Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trialsSonal Singh, Yoon K Loke, Paul L Enright, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|July 6, 2011
Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysisSonal Singh, Yoon K Loke, John G Spangler, et al.
The American Journal of Cardiology|January 12, 2005
Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)Paul L Canner, Curt D Furberg, Michael L Terrin, et al.
BMJ (Clinical Research Ed.)|November 13, 2012
Call for worldwide withdrawal of tiotropium Respimat mist inhalerRichard Beasley, Sonal Singh, Yoon K Loke, et al.
Pharmacoepidemiology and Drug Safety|February 11, 2016
Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014Thomas J Moore, Curt D Furberg, Donald R Mattison, et al.
JAMA|December 2, 2004
Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysisBruce M Psaty, Curt D Furberg, Wayne A Ray, et al.
Pageof 17

Showing results (71-80 of 169) with videos related to

Sort By:
Pageof 17
Progress in Cardiovascular Diseases|May 11, 2015
Is the Guideline Process Replicable and, if Not, What Does This Mean?Allan Sniderman, Curt D Furberg, Peter P Toth, et al.
Journal of Clinical Lipidology|December 3, 2010
Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?Allan Sniderman, Matt McQueen, John Contois, et al.
Journal of Clinical Lipidology|September 29, 2016
An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoBAllan D Sniderman, Peter P Toth, George Thanassoulis, et al.
Journal of Clinical Lipidology|December 3, 2010
When is equal not equal?Allan D Sniderman, Ken Williams, Matthew J McQueen, et al.
BMJ (Clinical Research Ed.)|June 16, 2011
Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trialsSonal Singh, Yoon K Loke, Paul L Enright, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|July 6, 2011
Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysisSonal Singh, Yoon K Loke, John G Spangler, et al.
The American Journal of Cardiology|January 12, 2005
Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)Paul L Canner, Curt D Furberg, Michael L Terrin, et al.
BMJ (Clinical Research Ed.)|November 13, 2012
Call for worldwide withdrawal of tiotropium Respimat mist inhalerRichard Beasley, Sonal Singh, Yoon K Loke, et al.
Pharmacoepidemiology and Drug Safety|February 11, 2016
Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014Thomas J Moore, Curt D Furberg, Donald R Mattison, et al.
JAMA|December 2, 2004
Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysisBruce M Psaty, Curt D Furberg, Wayne A Ray, et al.
Pageof 17